Company intelligence / Profile preview
Mucpharm
Sydney, New South Wales, Australiamucpharm.com ↗
- Ownership
- Private
- Development stage
- Phase 2
01
Overview
BromAc® is being explored in phase 2 studies for advanced cancers. The drug removes mucin from cancer cells and sensitizes them to chemotherapy agents. Clinical trials are also investigating BromAc® for respiratory conditions.
- Therapeutic areas
- OncologyPulmonology
- Modalities
- Small molecule drugEnzyme
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Global collaborative partnerships in Australia, the United States, Brazil, and Europe
Beyond the preview
Go deeper on Mucpharm.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Mucpharm.